MAGEA3 and osteosarcoma: As shown in Fig. 2A, CD8+ T cells cross-primed by γδ T-MAGEA3 or DC-MAGEA3 showed robust but comparable cytotoxicity against diverse MAGEA3+ osteosarcoma cell lines when evaluated by the LDH release assay.